Octagon Capital Advisors LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Octagon Capital Advisors LP
CRD #306424
SEC #801-118554
CIK #0001839435
AUM 1,175.3 M (2026-03-20)
Employees 10 (70% Investors, 0% Brokers)
Fees
Minimum
Phone212-369-2829
Address654 Madison Avenue, 21st Floor
New York, NY 10065
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($M)
120096072048024002010201520212027
In the News
Mon, 27 Jul 2026 Evommune, Inc. $EVMN Stake Lessened by Octagon Capital Advisors LP — MarketBeat
Mon, 27 Jul 2026 Octagon Capital Advisors LP Reduces Stock Holdings in Trevi Therapeutics, Inc. $TRVI — MarketBeat
Mon, 27 Jul 2026 Abivax SA Sponsored ADR $ABVX Shares Sold by Octagon Capital Advisors LP — MarketBeat
Mon, 27 Jul 2026 Octagon Capital Advisors LP Has $163.36 Million Position in Dianthus Therapeutics, Inc. $DNTH — MarketBeat
Mon, 27 Jul 2026 Octagon Capital Advisors LP Sells 324,110 Shares of BridgeBio Oncology Therapeutics, Inc $BBOT — MarketBeat
Fees and Compensation — Form ADV Part 2A (3/20/2026) [Brochure]
Item 5 – Fees and Compensation

PROSPECTIVE INVESTORS ARE STRONGLY ENCOURAGED TO CAREFULLY REVIEW NOT ONLY THIS BROCHURE, BUT
ALSO ANY APPLICABLE CONFIDENTIAL OFFERING MEMORANDA (“COM”). ALL DISCUSSIONS OR REFERENCES TO
ANY FUND IN THIS BROCHURE ARE QUALIFIED IN THEIR ENTIRETY AND MAY BE SUPPLEMENTED AND SUPERSEDED
BY THE APPLICABLE COM, SUBSCRIPTION AGREEMENT(S), AND/OR OTHER GOVERNING DOCUMENT(S)
(COLLECTIVELY, “FUND DOCUMENTS”).

A. Generally, we receive a management fee and an incentive allocation, where applicable and as described
   below, from the Funds. Fees vary both among the Funds and between a Fund’s share classes.

B. Management fees and incentive allocations, as well as other terms, are more fully described in each Fund’s
   respective Fund Documents. Typically, management fees for each applicable Fund are paid quarterly in
   advance based on the value of each Investor’s capital account as of the first day of each calendar quarter or
   the date of an Investor’s capital contribution, if other than the beginning of a quarter. In our sole discretion,
   we may waive or modify the management fee for certain Investors, including, but not limited to, members,
   partners, affiliates, or employees of Octagon or Octagon Investments GP, LLC (the “General Partner”),
   relatives of each such person, and trusts or other entities for their respective benefit(s).

    Fees related to the Octagon Special Opportunities Fund, LP, and each applicable series investment (the
    “Special Opportunities Fund”), which are received for consideration in each series investment’s capital
    commitments, due diligence, other services relating to financings or a Series’ exercise of management rights,
    including, without limitation, directors’ fees, commitment fees, closing fees, monitoring fees, transaction fees

    and investment banking fees (collectively, “Transaction Fees”) shall be paid to or retained by the General
    Partner, the Investment Manager or their Affiliates. For the avoidance of doubt, break-up fees, if any, from
    broken deals will not be treated as Transaction Fees, unless otherwise determined by the General Partner in
    its sole discretion.

    On a case by case basis, the General Partner, in its sole discretion, may waive a Fund’s management fees for
    some investors.

    Subject to any loss carryforward provisions (“High-Water Marks”) discussed in a Fund’s applicable Fund
    Documents, we also generally receive an incentive allocation from each Investor at the end of each calendar
    year via a reallocation from such Investor’s capital account to the General Partner’s capital account, calculated
    at a specified percentage based on the terms of the applicable Fund Documents.

    The General Partner or its affiliate receive performance compensation in the form of carried interest
    distributions where earned and subject to the terms of the applicable Fund Documents. Carried interest
    distributions made to the General Partner are subject to a “clawback” provision, where applicable, whereby
    the General Partner or its affiliates may be required to return carried interest distributions as defined in each
    Fund agreement. Such clawback may permit the General Partner to receive, as cash advance against carried
    interest distributions, an amount sufficient to enable the General Partner or its affiliate to satisfy its tax liability
    attributable to its right to receive such carried interest distributions.

C. Subject to the terms of the Funds’ Fund Documents, the Funds generally pay all costs and expenses related to
   its investments and its operations, including brokerage and other transaction costs (please see Item 12 for a
   discussion on our Brokerage Practices); data fees; clearing and settlement charges; outsourced trading service
   expenses; trade break fees; research (including research-related travel expenses incurred with respect to
   specific potential or existing investments and portfolio management systems) that fall within Section 28(e) of
   the Securities Exchange Act of 1934, as amended (the “Exchange Act”); fees paid to consultants providing
   services in respect of such systems; brokerage products, services, and systems (including order management
   systems); legal fees and other expenses in connection with conducting due diligence and negotiating the terms
   of investments (including investment-related travel expenses incurred with respect to specific potential or
   existing investments), regardless of whether such investments are consummated; investment-related
   expenses; custodial fees, consulting fees; directors’ and officers’ fees and expenses (including for individual
   regulatory filings referable to a Fund); administrator fees and expenses; third-party valuation services;
   expenses and costs of expert networks; expenses and costs of obtaining surveys, analysis, or other data sets
   from third-parties related to investments or sectors in which the Fund may invest; attending investor and
   industry related conferences; initial and variation margin, interest, and commitment fees on debit balances
   or borrowings; stock borrowing fees (including, without limitation, dividend payments on short positions) and
   proxy solicitation expenses; the amortized portion of organizational costs of the Funds (including a pro rata
   share organizational costs); legal expenses (including expenses relating to regulatory or similar investigations,
   inquiries and “sweeps”); audit and tax preparation expenses; accounting fees; insurance expenses including
   costs of any liability insurance obtained on behalf of the Funds or officers’ and directors’ insurance;
   government and regulatory costs and expenses (including filing and license fees and preparation and
   submission of filings and licenses, including Section 13 filings, Form PF preparation and filing fees, blue sky
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/20/2026) [Brochure]
Item 7 – Types of Clients

We provide investment advisory services to the Funds, which are pooled investment vehicles. The minimum initial
subscription amount for each Fund is generally $5,000,000, which we may, in our sole discretion, reduce or waive,
subject to statutory minimums.
Sector Form 13F Holdings Value ($M)
Magenta Therapeutics Inc 163.4
UNUM Therapeutics Inc 90.5
Abivax Sa 75.4
Alumis Inc 62.4
MIND Medicine Mindmed Inc 46.1
Arrivent Biopharma Inc 45.5
Taysha Gene Therapies Inc 39.6
Kymera Therapeutics Inc 35.4
Mirum Pharmaceuticals Inc 31.3
Bioage Labs Inc 30.6
View All
Holdings by Sector ($M)
100080060040020002021202320252027
Type Form D Funds Date Sold AUM
PE Octagon Biotech Opportunities Fund I LP [2025-03-17] 16.5 M 82.3 M
Offered $16,500,000 · Filed 2025-06-16 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Duration One year or less · Revenue Decline to Disclose
PE Octagon Special Opportunities Fund LP [2022-03-21] 5.0 M 13.3 M
Offered $5,000,000 · Filed 2021-05-24 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Net Assets Decline to Disclose
PE Octagon Coinvest Opportunities Fund LP [2021-03-18] 29.1 M 104.5 M
Offered $59,150,000 · Filed 2021-01-07 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining $30,000,000 · Duration One year or less · Revenue Decline to Disclose
HF Octagon Investments Master Fund LP [2019-11-08] 709.2 M 975.2 M
Filed 2025-12-05 (D/A) · Exemption 506(b), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 8 1,175.3
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 8 1,175.3
By Discretionary
Discretionary 8 1,175.3
Non-Discretionary 0 0.0
Total 8 1,175.3
By Non-United States Persons
Non-United States Persons 985.3
United States Persons 190.0
Total 8 1,175.3
Form D Directors Role # Filings # Firms 2011 - 2026
Jennifer Collins Director 232 47
Jonathan Morgan Director 50 12
Ting Jia Director, Executive Officer 16 2
Octagon Capital Advisors LP Promoter 13 2
Octagon Investments GP LLC Executive Officer 12 2
EDGAR Form CIK 2011 - 2026
13F-HR [0001839435]
SC 13G [0001839435]
Form 13D/13G Filer Form 13D/13G Subject Filed
Octagon Capital Advisors LP Context Therapeutics Inc [2026-05-14]
Octagon Capital Advisors LP Palisade Bio Inc [2026-02-10]
Octagon Capital Advisors LP Precision Biosciences Inc [2026-02-10]
Octagon Capital Advisors LP Gossamer Bio Inc [2025-02-05]
Octagon Capital Advisors LP Taysha Gene Therapies Inc [2025-02-05]
Octagon Capital Advisors LP Allovir Inc [2024-10-11]
Octagon Capital Advisors LP Arrivent Biopharma Inc [2024-10-11]
Octagon Capital Advisors LP Unicycive Therapeutics Inc [2024-10-11]
Octagon Capital Advisors LP Regulus Therapeutics Inc [2024-10-11]
Octagon Capital Advisors LP Dianthus Therapeutics Inc /DE/ [2024-10-11]
View All
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund, Private Equity
LEI549300LAL4WLS7BIZZ14
Comparable Firms State AUM
Wynkoop LLC
CO 1,217.3 M
Hudson Cove Capital Management LLC
NJ 1,213.5 M
Arlon Advisor LLC
NY 1,176.7 M
Cota Capital Management LLC
CA 1,167.9 M
Grafton Street Partners Management Company LLC
1,163.3 M
IBEX Investors LLC
CO 1,160.5 M
Forest Road Asset Management LLC
CA 1,158.5 M
Corre Partners Management LLC
NY 1,147.8 M
Winston Capital Management LLC
VA 1,147.2 M
Ivyrock Asset Management HK Limited
1,140.6 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com